{"entity":{"id":"paper-destiny-pantumor02-jco-2024","kind":"paper","name":"DESTINY-PanTumor02: trastuzumab deruxtecan in HER2-expressing solid tumours","aka":[],"tldr":"Across seven tumour types including endometrial, cervical and ovarian cancers, trastuzumab deruxtecan shrank tumours in about 37 percent of patients overall and 61 percent of those with the highest HER2 expression, leading to a tumour-agnostic approval.","summary":"Phase 2 study of 267 patients with previously treated HER2-expressing (immunohistochemistry 3+ or 2+) advanced solid tumours in seven cohorts (endometrial, cervical, ovarian, bladder, biliary, pancreatic and other) treated with trastuzumab deruxtecan 5.4 mg/kg.\n\nObjective response was 37.1 percent overall and 61.3 percent in immunohistochemistry 3+ tumours, with median duration of response 11.3 and 22.1 months respectively; endometrial (57.5 percent) and cervical (50.0 percent) cohorts responded best. Interstitial lung disease occurred in 10.5 percent.","asOf":"2026-09-17","links":[{"label":"J Clin Oncol 2024","url":"https://doi.org/10.1200/JCO.23.02005"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/37870536/"}],"tags":[],"related":[],"cancers":["endometrial-p53-abnormal","recurrent-metastatic-cervical-cancer","uterine-carcinosarcoma"],"sections":[],"technologies":[],"targets":[],"drugs":["trastuzumab","trastuzumab-deruxtecan"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["destiny-pantumor02"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["jco"],"dependsOn":[],"notes":[],"journal":"Journal of Clinical Oncology","year":2024,"doi":"10.1200/JCO.23.02005","pmid":"37870536","authors":"Meric-Bernstam F, Makker V, Oaknin A, et al.","paperType":"observational","findings":["Objective response 37.1 percent overall; 61.3 percent in immunohistochemistry 3+.","Endometrial cohort response 57.5 percent; cervical 50.0 percent."],"whatItMeans":"HER2 immunohistochemistry is now worth doing in advanced gynaecological and other cancers, since trastuzumab deruxtecan is approved for HER2 3+ solid tumours after prior therapy.","caveats":["Single-arm across heterogeneous tumours; responses in 2+ tumours were modest (27 percent).","Interstitial lung disease including fatal cases."],"changedPractice":true,"participants":267},"route":"/key-papers/paper-destiny-pantumor02-jco-2024/","neighbours":{"cancer":[{"id":"endometrial-p53-abnormal","kind":"cancer","name":"p53-abnormal endometrial cancer, including uterine serous carcinoma","route":"/cancers/endometrial-p53-abnormal/"},{"id":"recurrent-metastatic-cervical-cancer","kind":"cancer","name":"Recurrent or metastatic cervical cancer","route":"/cancers/recurrent-metastatic-cervical-cancer/"},{"id":"uterine-carcinosarcoma","kind":"cancer","name":"Uterine carcinosarcoma","route":"/cancers/uterine-carcinosarcoma/"}],"drug":[{"id":"trastuzumab","kind":"drug","name":"Trastuzumab","route":"/drugs/trastuzumab/"},{"id":"trastuzumab-deruxtecan","kind":"drug","name":"Trastuzumab deruxtecan","route":"/drugs/trastuzumab-deruxtecan/"}],"trial":[{"id":"destiny-pantumor02","kind":"trial","name":"DESTINY-PanTumor02","route":"/trials/destiny-pantumor02/"}],"journal":[{"id":"jco","kind":"journal","name":"Journal of Clinical Oncology","route":"/journals/jco/"}]}}